SCHEMBL6427997

SCHEMBL6427997

CCN(C(=O)CC1SC(NC2CCCCCC2)=NC1=O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.40
TSHR P16473 3/20 0.36
ALDH1A1 P00352 2/20 0.36
GLA P06280 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CASP3 P42574 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TP53 P04637 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6428801 0.90 NPC1 (0.42) PKMTSHRALDH1A1SMN1; SMN2HDAC1
SCHEMBL6429086 0.89 ALDH1A1 (0.40) ALDH1A1GLASMN1; SMN2HDAC1HDAC6
SCHEMBL6426356 0.89 PKM (0.48) PKMALDH1A1SMN1; SMN2CASP3MEN1
SCHEMBL6428237 0.89 PKM (0.48) PKMALDH1A1SMN1; SMN2CASP3MEN1
SCHEMBL6425910 0.87 PKM (0.46) PKMTSHRALDH1A1SMN1; SMN2CASP3
SCHEMBL6386580 0.86 ATM (0.37) PKMTSHRALDH1A1GLAMEN1
SCHEMBL6428317 0.83 PKM (0.40) PKMTSHRALDH1A1MEN1KMT2A
SCHEMBL6429839 0.80 ALDH1A1 (0.33) TSHRALDH1A1GLAMEN1KMT2A
SCHEMBL6427664 0.80 L3MBTL1 (0.39) ALDH1A1MEN1KMT2ALMNAL3MBTL1
SCHEMBL6426954 0.80 L3MBTL1 (0.39) ALDH1A1MEN1KMT2ALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US claimed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO claimed
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239853-A1 New compounds HSD11B1, CYP11B1, HSD3B1 PKM 1152/4885TSHR 2078/4885ALDH1A1 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.